We investigated the temporal changes in circulating levels of markers of extracellular cardiac matrix (ECCM) turnover and their relationship with infarct size (IS), ejection fraction (EF), and left ventricular (LV) volumes, determined by serial cardiac magnetic resonance (CMR) imaging in patients with first-time ST-elevation myocardial infarction (STEMI).
Introduction
Myocardial infarction (MI) initiates a complex process of repair within the infarct zone, with an adaptation to the loss of the functional myocardium within the non-infarcted myocardium. While this process may be compensatory, it may also aggravate left ventricular (LV) dysfunction via adverse remodelling, a structural, functional, and genetic process, leading to LV dilatation, abnormal geometry, and chronic volume overload. 1 There is an emerging understanding that dysregulation of the extracellular cardiac matrix (ECCM) is an active contributor to progressive LV remodelling causing either excessive collagen deposition with subsequent fibrosis 2 or insufficient collagen deposition and/or collagen degradation with subsequent LV dilatation. 3 Extracellular cardiac matrix turnover following MI may be assessed by circulating fragments of collagen synthesis and degradation, and by circulating levels of regulators of extracellular cardiac matrix degradation such as matrix metalloproteinase (MMPs) and their inhibitors, tissue inhibitors of metalloproteinases (TIMPs). 4 -9 Type I and III collagens are the major structural proteins of the ECCM in the human heart. 10 N-terminal type I procollagen (PINP) is considered to be a marker of type I collagen synthesis, whereas C-terminal telopeptide of type I collagen (ICTP) is a marker of collagen type I degradation. 11 Circulating levels of N-terminal type III procollagen (PIIINP) reflect type III collagen synthesis. 12 Several studies have demonstrated an association between increased MMP and TIMP levels and adverse outcome following MI. 13 -15 Circulating levels of both type I and type III collagen fragments have been shown to have prognostic value in patients who developed heart failure following MI. 16, 17 These findings suggest a relationship between markers of ECCM turnover and adverse LV remodelling. However, the dynamic relationship between these markers, infarct healing, and LV remodelling has not been elucidated adequately. The present study therefore analysed the temporal relationship between PINP, ICTP, PIIINP, MMP-2, -3, and -9, as well as TIMP-1, -2, and -4, infarct size (IS), and LV remodelling following a first acute ST-elevation MI (STEMI) in patients successfully treated by primary percutaneous coronary intervention (pPCI).
Methods

Study design
Only patients with a first-time STEMI, and an occluded, main single vessel at the time of coronary angiography, successfully treated by pPCI were included in the study. Infarct size and LV volumes and LV ejection fraction (EF) were determined by serial cardiac magnetic resonance (CMR) imaging 2 days, 1 week, 2 months, and 1 year following MI. To permit evaluation as early as possible, the first blood sample was acquired prior to opening of the infarct-related artery. Following pPCI, blood samples were acquired at the time of each CMR assessment. The correlations between the collagen markers and CMR assessment at 1 year following MI were the primary outcome variable.
Patients
The inclusion and exclusion criteria have been described previously. 18 Briefly, 42 patients with a first-time STEMI, defined by typical chest pain and ST-elevation on ECG at admission were recruited if they had demonstrated acute proximal/mid-occluded single vessel disease and underwent successful PCI with stent implantation and TIMI 3 flow without significant residual stenosis. The time of the debut of symptoms was estimated by the history. Patients were excluded if they had evidence of previous MI based on history, ECG findings, evidence of MI on angiography, or in more than one vascular territory on CMR examination. Eligible patients were required to have no contraindications to CMR imaging. Patients with evidence of reinfarction during the first week, chronic atrial fibrillation, known malignancy, or other concomitant chronic disease such as infectious or autoimmune disorders were excluded from participation. All the patients were treated with aspirin, heparin, clopidogrel, and statins according to the routine PCI procedure. Other medication was prescribed by the treating physician as indicated without knowledge of the CMR results. Twenty healthy, age-matched volunteers served as a control group for estimating normal values of circulating ECCM markers. The study was approved by the Regional Ethics Committee at the University of Bergen and all the patients provided written informed consent prior to inclusion.
Cardiac magnetic resonance protocol
The CMR protocol has been described previously. 18 The CMR images were ECG-gated and obtained during breath hold. Patients were scanned in a supine position by a 1.5 T whole body scanner (Intera   TM   R10 .3, Philips Medical Systems, Best, The Netherlands) using a dedicated cardiac coil. Resting LV function was determined with cine images using a steady-state free precession technique. For first-pass perfusion, a turbo field echo sequence with three short-axis slices per heart beat (prospective triggering) and a selective saturation recovery prepulse was used. Gadolinium-based contrast agent (Omniscan TM , Amersham Health, Little Chalfont, UK) was given at a dose of 0.075 mmol/kg. Immediately following the completion of the first-pass imaging, another 0.175 mmol/kg of contrast agent was infused, and 10 -15 min following the latter infusion-delayed hyperenhancement images were acquired. All post-processing was performed on the View Forum TM Software (Philips Medical Systems, Best, The Netherlands) in a random, blinded fashion. Assessment of body surface indexed end-diastolic (LVEDVi), end-systolic (LVEDVSi), and EF was done by short-axis volumetry. Infarct size was assessed manually with planimetry on each short-axis slice by delineating the hyperenhanced area from the non-enhanced myocardium.
Blood sampling protocol
Venous blood samples were collected on admission to the hospital, immediately prior to PCI, and 2 days, 1 week, 2 months, and 1 year following MI. The pyrogen-free blood collection tubes were immediately immersed in melting ice (ethylenediaminetetraacetic acid-containing tubes, plasma) or placed in room temperature (tubes without any additives, serum) and centrifuged within 20 min at 2500 g for 20 min to obtain platelet-poor plasma or centrifuged at 1000 g for 10 min after coagulation (serum). All samples were stored at 2808C and thawed only once.
Analysis of biomarkers
Plasma MMP-2, -3, and -9 and TIMP-1, -2, and -4 were analysed as previously described. 13, 19, 20 N-terminal type III procollagen, PINP, and ICTP levels were analysed using a radioimmunoassay from Orion Diagnostica (Finland). The lower detection limit was 0.20 ng/mL for PIIINP, 2.0 ng/mL for PINP, and 0.50 ng/mL for ICTP. High-sensitive C-reactive protein (hsCRP) concentrations were measured by a particle-enhanced immunoturbidimetric method with the use of Roche ModularP automated clinical chemistry analyser (Roche Diagnostics, Basel, Switzerland) and reagents of the Tina-quant C-reactive protein (latex) assay (Roche Diagnostics). N-terminal pro-brain natriuretic peptide (NT-proBNP) was measured with a Roche Diagnostics NT-proBNP assay on an Elecsys 2010 analyser (Roche Diagnostic).
Troponin-T (TnT) concentrations were measured on Roche Elecsys 2010 (Roche Diagnostics), with the immunoassay TnT (Roche Diagnostics), using biotinylated monoclonal TnT-specific antibody and a monoclonal TnT-specific antibody labelled with ruthenium forming a sandwich complex.
Inter-and intra-assay variations ranged from 2.7-5.3% for all ECCM markers.
Statistical analyses
The mean and standard error of the mean (SEM) were calculated for continuous variables. A general linear model with ANOVA for multiple measurements was used to test for time-dependent changes of ECCM markers. Between time-point measurements were corrected for multiple measurements by a Bonferroni correction. Univariate correlations C. Manhenke et al.
were performed using non-parametric methods (Spearman). Multiple regression (backward stepwise) was used to test the independent contribution of IS, the mass of the non-scarred myocardium to LV volumes and EF on each ECCM turnover marker. To assess the prognostic value of each marker, a univariate non-parametric correlation was performed. Thereafter, all circulating markers were included in the multivariable linear backward stepwise model, and each CMR finding at 1 year was included as a dependent variable. Testing for collinearity was performed by estimation of the variance inflation factor and tolerance statistics and indicated that the degree of collinearity with circulating TnT may be considered negligible. At the given sample size, we calculated an 80% probability to detect changes that exceeded 60% of the within patient standard deviation of the response variable. Post hoc analysis revealed a statistical power for baseline blood samples vs. LVEDVi, LVESVi, and EF of 89, 53, and 90%, respectively. For longitudinal measurements, the sample size calculation was based upon previous studies that found intra-assay CV of 3.5-4.3% and intra-individual variation of 3.5 -20%. 21, 22 Our own calculations of intra-assay variation are 2.7, 5.3, and 5.1% for PIIINP, PINP, and ICTP, respectively. Taken together, and calculating with an intra-assay CV of 5% and an intra-individual CV of 25%, which is higher than we could find in the literature, our study would need 18, 14, and 14 individuals for PIIINP, PINP, and ICTP, respectively, to detect a 25% increase with a power of 0.8 and a two-sided a ¼ 0.05. For all statistical analyses, a commercially available statistical package (SPSS system 17.0) was used.
Results
Baseline characteristics and cardiac magnetic resonance findings
The baseline characteristics in the 42 patients included in this study are presented in Table 1 . The median time from symptom debut to admission was 145 min (range: 25-720 min). Extracellular cardiac matrix-marker analyses from admission samples were available in 35 patients. With the exception of one patient who was unable to attend the final CMR examination at 1 year, all 42 patients underwent all CMR examinations. The first CMR examination was performed at a mean of 2.2 + 0.1 days following pPCI, the second at 7.3 + 0.1 days, the third at 61 + 0.6 days, and the fourth 364 + 1.2 days following MI. As previously reported, 18 there was a significant reduction in IS (P , 0.001) and LVESVi (P , 0.001), and a significant increase in LVEF (P , 0.002) from 2 days until 1-year follow-up, whereas LVEDVi did not change ( Table 2) . Inhibitors of the reninangiotensin-aldosterone system (RAAS) were initiated between 24 and 36 h following pPCI according to department routines. In 13 patients (31%), uptitration to the maximum recommended dose was completed within 1 week following MI. Within 2 months of follow-up, uptitration to target dose as recommended by the ESC guidelines was reached in 27 patients (64%). 23 The combination of either an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB) with an aldosterone antagonist was initiated in seven patients (17%).
Longitudinal profile of extracellular cardiac matrix markers
With the exception of TIMP-2 and TIMP-4, ECCM markers showed significant time-dependent changes (P , 0.01 for trend) in their circulating levels during the follow-up ( Figure 1) . Several significant patterns were demonstrated. First, while ICTP levels were within normal range at baseline, when compared with controls, they showed a rapid and significant increase after 2 days, with persistently raised levels during the whole entire observation period. Secondly, while PINP showed a late increase during the follow-up reaching the highest levels at 1 year, PIIINP showed a rapid increase (2-7 days), with persistently raised levels throughout the observation period, indicating a shift to of type III collagen deposition during the first week following MI. However, except for slightly decreased PIIINP levels during the first week, PINP, and PIIINP levels were within normal limit throughout the observation period. Thirdly, while MMP-2 levels were markedly reduced when compared with controls at baseline, with a significant increase after 2 months before returning to baseline levels after 1 year, baseline MMP-9 levels were markedly increased when compared with controls. This was followed by a rapid decrease after 2 days, with persistently decreased levels when compared with baseline throughout the observation period, with a slight increase from 2 days to 1 week. Fourth, MMP-3 showed a gradual and significant decrease during the follow-up, with levels slightly lower than in controls throughout the observation period. Finally, while there were no changes in TIMP-2 and TIMP-4, TIMP-1 showed a gradual and significant decrease during the follow-up, declining from within to below normal limit from baseline to 1 year.
The association of extracellular cardiac matrix markers and cardiac magnetic resonance variables at 1 year: univariate analysis
Significant correlations to CMR findings at 1 year were found for PINP, MMP-2, MMP-3, TnT, NT-proBNP, and high-sensitive C-reactive protein ( Table 3) . The time-point of blood sampling appears to be of essential importance, consistent with the longitudinal profiles of the ECCM markers (Figure 1) . The association of extracellular cardiac matrix markers and cardiac magnetic resonance variables at 1 year: multivariable analysis Table 4 displays the results from multivariable linear regression analyses for CMR findings at 1 year. Several findings were revealed. First, baseline levels of PINP were negatively associated with LVEDVi, LVESVi, and IS and positively associated with EF at 1 year. With regard to EF, a similar association was also found for PINP levels after 2 days. Secondly, a similar association pattern was found for MMP-2 levels after 7 days, with a significant negative association with LVEDVi, LVESVi, and IS and a significant positive association with EF at 1 year. As for LVESVi and EF, similar associations were found for MMP-2 levels at baseline. In contrast, an opposite pattern of associations was found for MMP-3, with a positive association with LVEDVi, LVESVi, and IS and a negative association with EF after 1 year. As for LVEDVi and LVESVi, similar associations were also found for MMP-3 levels at 2 days. Infarct localization as an additional covariate did not affect the results of the multivariable regression models.
The association of extracellular cardiac matrix markers and cardiac magnetic resonance findings at the four different time-points An identical multivariable linear regression analysis was conducted for the CMR time-points at 2, 7 days, and 2 months post-AMI. Among biomarkers assessed prior to PCI, PINP was the only independent significant predictor for IS and remodelling parameters at all examination time-points ( Table 5) .
At 2 days, TnT was the strongest predictive biomarker for all CMR parameters at all estimation time-points (P-values between ,0.01 and ,0.001) reflecting the strong association between TnT and IS. Among the other biomarkers, significant b-values at all three imaging time-points were seen for MMP-9 (LVEDVi, P-values between ,0.05 and ,0.001) and high-sensitive C-reactive protein (IS and EF inversely, P-values between ,0.05 and ,0.01). N-terminal procollagen type I significantly predicted EF at 7 days (P , 0.05). There was a modest correlation between PINP and TnT values at 2 days (r ¼ 20.31, P ¼ 0.04) but no significant correlation between PINP and high-sensitive C-reactive protein (r ¼ 20.20, P ¼ 0.2) or NT-proBNP (r ¼ 20.28, P ¼ 0.07). It is noteworthy that NT proBNP did not predict LV volumes estimated at 2 and 7 days, but was significantly associated with LV volumes at 2 months (P , 0.05 -P , 0.01).
At 7 days, MMP-2 and MMP-3 appeared to be the major predictors of outcomes. Both markers were consistent predictors of LV volumes estimated at 7 days and 2 months (P , 0.05 and P , 0.001). Matrix metalloproteinase-3 was the only independent predictor of IS for all given time-points (P , 0.05).
Discussion
The present study presents three important and novel findings indicating sustained changes in collagen homoeostasis following MI. First, there was a significant increase in type I collagen degradation (ICTP) following MI that was maintained beyond the subacute healing phase. Secondly, this early increase in ICTP was not accompanied by an increase in PINP, a marker of type I collagen synthesis. A gradual increase in PINP levels was observed 2 months and 1 year after MI. Thirdly, in contrast to the delay in type I collagen synthesis, there was an immediate increase in type III collagen synthesis (PIIINP) following MI. Taken together, these findings suggest a net type I collagen breakdown in the early phase following MI compensated by an early increase in type III collagen synthesis during this period (Figure 1) . Furthermore, syntheses of both type I and type III collagens remained elevated in the chronic phase of MI (1 year), suggesting a sustained pro-fibrotic state in the late remodelling phase. 
Type I and III collagen
Circulating levels of both type I and type III collagen fragments have been shown to have a prognostic value in patients developing heart failure following MI. 16, 17 These studies sampled PINP and PIIINP in the subacute phase post-MI. There are limited data on the dynamic changes in these markers early post-MI, and no study has assessed the relationship between these markers, infarct healing and LV remodelling assessed by CMR. The observed increase in type III collagen synthesis is in accordance with the importance of type III collagen in early wound healing and remodelling after STEMI. 24 An increased deposition of type III collagen has been demonstrated in the chronic phase of infarct healing in rats, 25 and recently, persistent elevation of serum-PIIINP has been demonstrated in stable elderly heart failure patients with or without preserved LV systolic function. 26 Type III collagen has different functional characteristics when compared with type I collagen; while type I collagen confers tensile strength and resistance to stretch and deformation, type III collagen fibres confer resilience. Alterations in collagen deposition during the scar development in the early phase of wound healing following acute MI appear to be associated with the development of infarct expansion and the pathogenesis of myocardial rupture. 27 In acute MI, circulating PIIINP is associated with markers of oxidative stress, inflammation, cell death, and tissue injury. 28 Although we do not have a reliable marker of type III collagen breakdown, the sustained increase in type III collagen synthesis, reflected by prolonged elevation of PIIINP between 2 days and 1 year, may suggest a continued shift towards a more vulnerable ECCM with an increase in type III collagen content. Despite optimized therapy, adverse LV remodelling still frequently occurs in patients with transmural MI. 18 The persistent predominant increase in type III over type I collagen implies that the window for active adverse remodelling may extend beyond the subacute healing phase following MI. Thus, therapeutic approaches designed to limit a type I to type III collagen shift in the ECCM post-MI might attenuate LV dilation and progressive functional loss of the myocardium. During the first week following MI, there was a strong relationship between circulating collagen fragments and LV remodelling. , squared multiple regression coefficient for analysis. *P , 0.05. **P , 0.01. ***P , 0.001. collagen levels and CMR findings was observed. This may reflect the increased use of anti-remodelling pharmacological therapy in patients with the worst LV function during the follow-up. At baseline, and 2 days following MI most patients were naive to RAAS inhibition, or had just initiated therapy. In contrast, 1 week following MI, antiremodelling therapy had been initiated and uptitrated in most patients. Patients with the largest MI received the most comprehensive RAAS inhibition. The use of ACEi/ARB and aldosterone antagonists has a profound effect on collagen turnover. 29 Therefore, the expected increase in collagen turnover in patients with the most profound LV remodelling may have been attenuated by a more comprehensive anti-remodelling therapy in these patients. Although it is tempting to speculate concerning the impact of our findings with regard to the ideal timing, dosage, and treatment duration of pharmacological anti-remodelling therapy, we prefer to emphasize that this study was not designed to address this issue. Whether very early initiation of RAAS inhibition, i.e. in the hyperacute phase of STEMI, and/ or prolonged therapy, would further attenuate adverse remodelling, would be a fruitful and clinically relevant research question. Similarly, the question of whether markers of ECCM turnover would be useful in identifying the patient population most likely to benefit from adequate RAAS inhibition and permit tailored therapy deserves to be addressed in future research.
The independent predictive value of PINP assessed as early as 145 min after symptom onset (median) was unexpected and has not been reported before. However, the consistency of our findings at all imaging time-points and for all parameters of cardiac remodelling suggests that PINP might serve as a very early prognostic marker of LV remodelling. Only one study has estimated the prognostic effects of early PINP measurements in patients following acute MI. 30 However, these investigators were not able to document significant differences between patients and a control group. The careful selection of patients and the precise estimation of remodelling parameters by CMR in our study reduced the heterogeneity of the results and thus might explain our significant findings. More recently, a substudy of the EPHESUS trial looked at the longitudinal profile of circulating markers of collagen turnover and their relation to clinical outcome. 17 N-terminal procollagen type I levels did not predict outcomes, however, as first blood sampling followed the inclusion timepoint of the EPHESUS trial, PINP sampling occurred 3-14 days after acute MI. Taken together, our findings suggest that the predictive value of PINP may be restricted to the hyperacute phase of MI, when established markers of remodelling fail to predict outcome. These findings are intriguing but remain only hypothesis generating. N-terminal type III procollagen has been reported as a prognostic marker in both chronic heart failure 31 and the subacute phase of MI. 32 Consistent findings in our analyses were only found for the prediction of IS at 7 days post-AMI, when PIIINP was assessed at the same time-point.
Matrix metalloproteinases and tissue inhibitors of metalloproteinases
The physiological integrity of ECCM structure is largely under the control of the MMP family of endopeptidases and their specific tissue inhibitors, TIMPs. defined, circulating levels of MMP-9 and MMP-2, and MMP-3 and TIMPs been implicated in the structural changes occurring after MI 14, 20 and have been related to adverse outcome. 13, 15 However, animal studies indicate that interfering with the orchestral interplay of MMPs and TIMPs might yield deleterious effects on remodelling and prognosis. 33 Specific pharmacological inhibition of MMP activity might attenuate adverse post-MI remodelling and this has been a focus of research interest. It has been demonstrated that successful MMP inhibition in mice post-MI is time sensitive and that long-term inhibition might have deleterious instead of beneficial effects for outcome. 34 Our study helps elucidate the longitudinal profile of MMP and TIMP levels in patients following acute MI. Circulating MMP-9 showed a biphasic longitudinal profile with markedly elevated levels in the hyperacute phase of MI. These high levels at admission had no prognostic impact on remodelling in our patients. Interestingly, levels of MMP-9 at 2 days post-MI had a significant inverse predictive value for LV volumes for up to 2 months, implying that low levels of MMP-9 predicted larger LV volumes. The second rise of MMP-9 at 1 week was inversely related to EF at 7 days and 1 year, i.e. higher levels of MMP-9 were associated with lower EF. MMP-2 and MMP-3 were below normal control levels and levels assessed at 7 days showed a conclusive pattern for prediction of LV volumes, EF and IS at 7 days and 1 year. While MMP-3 levels were directly related to CMR outcomes, MMP-2 revealed an inverse relationship. This paradoxical and highly time-dependent pattern underscores the complexity in MMP activity and emphasizes the potential risks that have to be confronted when applying pharmacological intervention on the MMP pathway: unless carefully timed and appropriately targeted, a deleterious effect on outcomes must be anticipated.
The levels of TIMP were largely within the normal range. Only the levels of TIMP-1 at 2 months and 1 year were clearly below the control group values. Although within the 95% confidence intervals of the control group, TIMP-1 levels assessed at 2 days were predictive for LV volumes at 2 days and 7 days in model 1 ( Table 2) . After adding established markers of remodelling to the model (Table 3) , the data were no longer consistent.
Limitations
The following important limitations should be noted. First, the present study assessed circulating levels of markers of collagen turnover. We cannot be certain that these levels reflect intracardiac changes in collagen composition. However, distinct profiles following revascularization of STEMI could be observed, and there was a strong relationship with CMR findings strongly suggestive of a relationship between these circulating markers and intramyocardial changes in the ECCM composition. It is noteworthy that direct measurements of intracardiac levels of collagen within the myocardium would require invasive procedures that would influence the circulating levels of the collagen markers confounding our measurements. Secondly, the relatively small sample size in this study makes the results susceptible to the impact of biological heterogeneity. However, the trial was designed with rigorous selection criteria in order to recruit a cohort with similar pathophysiological characteristics and reduce the number of confounders. The cohort therefore represents a unique and homogenous patient sample that facilitates interpretation of the prospectively selected parameters. Thirdly, treatment of the present cohort was necessarily consistent with conventional guidelines. 23 As expected there was a trend towards an increased use of comprehensive neurohormonal inhibition in patients with signs or symptoms of heart failure or evidence of LV dysfunction. The use of neurohormonal inhibition has been shown to affect levels of ECCM turnover following MI. 17 If less comprehensive neurohormonal inhibition had been administered, a larger increase in collagen markers might have been anticipated. Therefore, our results on LV remodelling are only applicable to STEMI patients treated with primary PCI and comprehensive RAAS inhibition resulting in a modest degree of adverse cardiac remodelling. Fourthly, we only analysed selected MMPs and TIMPs and therefore may have oversimplified the overall pattern of this complex orchestral interplay of MMP and TIMP activity. Furthermore we did not measure MMP activity.
Conclusions
Our findings indicate a net type I collagen breakdown in the early phase following revascularized STEMI associated with an early and persistent increase in collagen type III synthesis. An increase of type I collagen synthesis was delayed for 1 week following MI. N-terminal procollagen type I assessed at admission prior to pPCI was a strong independent predictor of IS and LV remodelling for up to 1 year following STEMI.
